Henry Schein, Inc.
HSIC Healthcare Medical - Distribution NASDAQ
$77.54
$-0.68 (-0.87%)
Open: $78.22 | High: $78.22 | Low: $76.73 | Prev Close: Prev Close: $78.22
Market Cap: $8.90B
Volume: 822K | Avg: 1.3M
Last updated: April 24, 2026 at 08:02 PMInvestment Rating
Neutral
Overall Score: 60/100
Rating Breakdown:
Stock Score Analysis
Stock Score: 507
Comprehensive Quality Assessment
Component Breakdown:
Valuation Metrics
| P/E Ratio | 23.71 |
| P/B Ratio | 2.80 |
| P/S Ratio | 0.67 |
| EPS | $3.27 |
| Beta | 0.88 |
| Shares Outstanding | 114.75M |
| 52-Week High | $89.29 |
| 52-Week Low | $61.95 |
| SMA 50 | $76.93 |
| SMA 200 | $72.49 |
| Next Earnings | May 04, 2026 12:30 PM ET |
Financial Ratios
| Gross Margin | 29.1% |
| Operating Margin | 5.8% |
| Net Margin | 3.0% |
| ROE | 11.9% |
| ROA | 3.5% |
| Debt/Equity | 1.14 |
| Current Ratio | 1.38 |
| Quick Ratio | 0.76 |
Balance Sheet
| Total Assets | $11.21B |
| Total Liabilities | $6.42B |
| Total Equity | $3.25B |
|
|
|
| Cash | $156.00M |
| Total Debt | $3.69B |
| Net Debt | $3.53B |
Income Statement
| Revenue | $13.18B |
| Gross Profit | $3.84B |
| Operating Income | $758.00M |
| Net Income | $398.00M |
|
|
|
| EBITDA | $1.01B |
| Revenue/Share | $112.34 |
Cash Flow
| Operating CF | $712.00M |
| CapEx | $139.00M |
| Free Cash Flow | $573.00M |
|
|
|
| Book Value/Share | $40.85 |
| Tangible Book/Share | $-3.72 |
| Equity/Share | $27.65 |
Technical Indicators
| RSI (14) | 63.59 Neutral |
| MACD |
0.81
Signal: 0.44
|
| Volatility | 24.79% |
| Trading Signal | Bullish |
Performance & Returns
| 1 Year | +4.56% |
| Sharpe Ratio | 0.17 Fair |
| Volatility (Ann.) | 29.92% Moderate |
| HSIC (1Y) | +4.56% |
| S&P 500 (1Y) | +14.41% |
| Alpha (Excess Return) | -9.85% |
Sector Comparison (Healthcare)
| Metric | HSIC | Sector Avg | Percentile |
|---|---|---|---|
| P/E Ratio | 23.71 | 26.29 | 44% |
| P/B Ratio | 2.8 | -21.07 | 46% |
| ROE (%) | 11.92% | -10.13% | 42% |
| Net Margin (%) | 3.02% | 9.57% | 24% |
| Stock Score | 507 | 540.0 | 28% |
| 1Y Return (%) | +4.56 % | +5.15 % | 55% |
📊 Historical Price Analysis (Last 200 Days)
Loading chart...
Technical Analysis
| Ticker | Close | SMA 5 | SMA 8 | SMA 13 | SMA 50 | SMA 200 | RSI (14) | MACD | Volatility (%) | Volume | Signal | SMA Decision |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HSIC | $77.54 | $78.85 | $78.44 | $77.33 | $76.98 | $72.52 | 63.59 | 0.81 | 24.79% | 56883 | Weak Short | Bullish Stack |
Candlestick Patterns
There wasn't any recognizable pattern for the HSIC stock
News Sentiment
| Ticker | Headline | Sentiment | Source | URL |
|---|---|---|---|---|
| HSIC | Henry Schein to Webcast First Quarter 2026 Conference Call on Tuesday, May 5, 2026, at 8:00 A.M. ET | Neutral | businesswire.com | Read More |
| HSIC | Why Henry Schein (HSIC) is Poised to Beat Earnings Estimates Again | Positive | zacks.com | Read More |
| HSIC | Here's Why Henry Schein (HSIC) is a Strong Value Stock | Neutral | zacks.com | Read More |
| HSIC | Why Henry Schein (HSIC) is a Top Growth Stock for the Long-Term | Positive | zacks.com | Read More |
| HSIC | Henry Schein to Reduce Size of the Board of Directors following 2026 Annual Meeting of Stockholders | Neutral | businesswire.com | Read More |
Recent Insider Trading
| Date | Insider | Position | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-03-19 | Popeck Thomas C | officer: CEO, Henry Schein Products | SELL | 1355 | $72.79 | $98630 |
| 2026-03-16 | South Ronald N. | officer: SVP & Chief Financial Officer | SELL | 5216 | $74.61 | $389166 |
| 2026-03-16 | Sheehy Christine Zayac | officer: SVP, Chief Human Res. Officer | SELL | 463 | $74.61 | $34544 |
| 2026-03-16 | Popeck Thomas C | officer: CEO, Henry Schein Products | SELL | 587 | $74.61 | $43796 |
| 2026-03-16 | MLOTEK MARK E | officer: EVP, Chief Strategic Officer | SELL | 5928 | $74.61 | $442288 |
| 2026-03-16 | Ettinger Michael S | officer: EVP & Chief Operating Officer | SELL | 4214 | $74.61 | $314407 |
| 2026-03-16 | Albertini Andrea | officer: CEO, Global Dist. & Tech. | SELL | 1401 | $74.61 | $104529 |
Company Information
Henry Schein, Inc. provides health care products and services to dental practitioners and laboratories, physician practices, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services. The Health Care Distribution segment offers dental products, including infection-control products, handpieces, preventatives, impression materials, composites, anesthetics, teeth, dental implants, gypsum, acrylics, articulators, abrasives, dental chairs, delivery units and lights, X-ray supplies and equipment, personal protective equipment, and high-tech and digital restoration equipment, as well as equipment repair services. This segment also provides medical products comprising branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, X-ray products, equipment, and vitamins. The Technology and Value-Added Services segment offers software, technology, and other value-added services that include practice management software systems for dental and medical practitioners. This segment also provides value-added practice solutions, which comprise financial services on a non-recourse basis, e-services, practice technology, network, and hardware services, as well as continuing education services for practitioners, and consulting and other services. Henry Schein, Inc. was founded in 1932 and is headquartered in Melville, New York.
| CEO | Andrea Albertini |
| Employees | 25000 |
| Country | US |
| IPO Date | 1995-11-03 |
| Exchange | NASDAQ |
| Website | https://www.henryschein.com |
| Sector | Healthcare |
| Industry | Medical - Distribution |
Similar Stocks (Healthcare - Medical - Distribution)
Rating Metrics Explained
DCF Score (Discounted Cash Flow)
Measures the intrinsic value of the stock based on projected future cash flows. A higher score indicates the stock is undervalued relative to its DCF valuation.
ROE Score (Return on Equity)
Evaluates how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better profitability and management effectiveness.
ROA Score (Return on Assets)
Measures how efficiently a company uses its assets to generate profit. A higher ROA means better asset utilization and operational efficiency.
D/E Score (Debt-to-Equity)
Assesses the company's financial leverage and risk. Lower debt-to-equity ratios indicate less financial risk and better balance sheet health.
P/E Score (Price-to-Earnings)
Compares stock price to earnings per share. A lower P/E ratio may indicate the stock is undervalued, while a higher ratio could suggest overvaluation or growth expectations.
P/B Score (Price-to-Book)
Compares market price to book value per share. Lower P/B ratios may indicate undervaluation relative to the company's net asset value.
Rating Recommendations:
Each metric is scored on a scale of 1-5, where the scores are determined by comparing the company's performance against industry benchmarks and historical data:
-
Strong Buy (5/5): Excellent score - strong positive indicator
- The metric significantly outperforms industry averages (top 20% of companies)
- Indicates exceptional financial health or attractive valuation in that category
-
Buy (4/5): Good score - positive indicator
- Above-average performance (top 40% of companies)
- Shows strong fundamentals with room for improvement
-
Neutral (3/5): Average score - neutral indicator
- Performance in line with industry median (middle 20%)
- Neither significantly positive nor negative signal
-
Sell (2/5): Below average - negative indicator
- Below-average performance (bottom 40% of companies)
- Suggests weakness in this particular metric
-
Strong Sell (1/5): Poor score - strong negative indicator
- Significantly underperforms industry (bottom 20%)
- Indicates potential risk or overvaluation in that category